Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Gestational diabetes and maternal obesity are associated with epigenome-wide methylation changes in children

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The R213G polymorphism in SOD3 protects against allergic airway inflammation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Experimentally induced testicular dysgenesis syndrome originates in the masculinization programming window

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. HDL activation of endothelial sphingosine-1-phosphate receptor-1 (S1P1) promotes regeneration and suppresses fibrosis in the liver

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Biofilm in group A streptococcal necrotizing soft tissue infections

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prognostic value of ratio of transmitral early filling velocity to early diastolic strain rate in patients with Type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The Liver-α-Cell Axis and Type 2 Diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  4. Renoprotection with Semaglutide and Liraglutide: Direct or Indirect Effects?

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

View graph of relations

BACKGROUND: Metformin reduces plasma glucose and has been shown to increase glucagon-like peptide 1 (GLP-1) secretion. Whether this is a direct action of metformin on GLP-1 release, and whether some of the glucose-lowering effect of metformin occurs due to GLP-1 release, is unknown. The current study investigated metformin-induced GLP-1 secretion and its contribution to the overall glucose-lowering effect of metformin and underlying mechanisms in patients with type 2 diabetes.

METHODS: Twelve patients with type 2 diabetes were included in this placebo-controlled, double-blinded study. On 4 separate days, the patients received metformin (1,500 mg) or placebo suspended in a liquid meal, with subsequent i.v. infusion of the GLP-1 receptor antagonist exendin9-39 (Ex9-39) or saline. During 240 minutes, blood was sampled. The direct effect of metformin on GLP-1 secretion was tested ex vivo in human ileal and colonic tissue with and without dorsomorphin-induced inhibiting of the AMPK activity.

RESULTS: Metformin increased postprandial GLP-1 secretion compared with placebo (P = 0.014), and the postprandial glucose excursions were significantly smaller after metformin + saline compared with metformin + Ex9-39 (P = 0.004). Ex vivo metformin acutely increased GLP-1 secretion (colonic tissue, P < 0.01; ileal tissue, P < 0.05), but the effect was abolished by inhibition of AMPK activity.

CONCLUSIONS: Metformin has a direct and AMPK-dependent effect on GLP-1-secreting L cells and increases postprandial GLP-1 secretion, which seems to contribute to metformin's glucose-lowering effect and mode of action.

TRIAL REGISTRATION: NCT02050074 (https://clinicaltrials.gov/ct2/show/NCT02050074).

FUNDING: This study received grants from the A.P. Møller Foundation, the Novo Nordisk Foundation, the Danish Medical Association research grant, the Australian Research Council, the National Health and Medical Research Council, and Pfizer Inc.

Original languageEnglish
JournalJCI Insight
Volume3
Issue number23
Pages (from-to)93936
ISSN2379-3708
DOIs
Publication statusPublished - 6 Dec 2018

ID: 55793924